Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Raftlin-2 CRISPR/Cas9 KO Plasmid (h): sc-414360
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Raftlin-2 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the Raftlin-2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Raftlin-2 Antibody (F-7): sc-514540
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Raftlin-2 CRISPR/Cas9 KO Plasmid (h) | sc-414360 | 20 µg | $397.00 |
Overview
RFTN2 encodes Raftlin-2, a lipid raft–associated scaffold protein that helps organize membrane microdomains involved in immune receptor signaling. Raftlin-2 supports trafficking and stabilization of signaling complexes in lymphoid cells, contributing to B cell receptor–proximal events, downstream kinase cascades, and regulated endocytosis. Through its role in coordinating raft-dependent signal transduction, RFTN2 is relevant to studies of immune cell activation, antigen responsiveness, and inflammatory pathway modulation. Altered expression or function is of interest in mechanistic research on immune dysregulation, including contexts linked to autoimmunity and hematologic disease biology.
Raftlin-2 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the RFTN2 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the RFTN2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the RFTN2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Raftlin-2 protein expression.
This CRISPR knockout system enables efficient generation of RFTN2-deficient cell models for investigation of Raftlin-2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting RFTN2 exon(s) critical for Raftlin-2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple RFTN2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by Raftlin-2 CRISPR/Cas9 KO Plasmid (h) and Raftlin-2 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the RFTN2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by Raftlin-2 HDR Plasmid (h) and Raftlin-2 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by RFTN2 homology arms to support homology-directed repair at defined RFTN2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.